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Abstract
Objective: The aim of this work was to assess the antifungal and post-antifungal effects of chlorhexidine, flucona-
zole, chitosan and its combinations on virulence factors of Candida albicans.
Study Design: Ten isolated strains of Candida albicans obtained from 10 patients with oral candidiasis and a 
collection strain of C. albicans were treated with antifungal agents in different concentrations or combinations 
of them. Virulence factors analyzed were the cell surface hydrophobicity, the germinative tube development, the 
phospholipase activity and the post-antifungal effect of that exposure.
Results: Virulence factors of the isolated strains obtained from patients together with the collection strain showed 
significant decreases with the different antifungal treatments, except for hydrophobicity and phospholipase activ-
ity. The development of germinative tube was the most sensitive factor to all the antifungal agents used. Untreated 
strains as well as the ones treated with antifungal agents showed a positive correlation among the virulence factors 
analyzed. No synergic effects arose from the combinations of the used drugs. 
Conclusions: C. albicans isolated strains from patients showed high phospholipase activity and germinative tube 
production, which corroborates their capacity to infect the oral mucosa and the high prevalence of species. As 
a whole, our results imply that short exposures to sub-inhibitory concentrations of the antifungal agents under 
analysis, isolated or combined, can modulate the way virulence factors get manifested, thus decreasing their 
pathogenicity.
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Introduction
Candida genus is composed of more than 150 different 
species, but Candida albicans is the main responsible 
species for oral candidiasis. An increase in the percent-
age of colonized people has been observed according 
to their age and the presence of predisposing local or 
general factors (1,2). The first stage of the infection in-
cludes adhesion to cellular surfaces. Adhesion of yeast 
has been studied using buccal epithelial cells, different 
cell lines, and plastic materials (3,4), with the cell sur-
face hydrophobicity of fungus (CSH) as the main force 
implied in this process (5). Besides, C. albicans is ca-
pable of secreting exoenzymes, such as phospholipase 
(PL), and of developing hyphae, which allows penetra-
tion in oral tissues and, in turn, the infection process 
(6,7). Another form of measuring the yeast virulence is 
through the post antifungal effect (PAFE), which meas-
ures the growth recovery capacity after a limited expo-
sure to antifungal agents (8). 
In recent years, an increase of resistance to some anti-
fungics agents has been observed and this has caused 
concern due to the eukaryotic character of Candida as 
well as of host cells, and due to a smaller number of 
available antifungal drugs compared to antibiotics (9). 
Some clinical research has used some chlorhexidine-
based (CLX) oral rinses as an alternative to antifungal 
agents used regularly, obtaining good results (10); while 
other studies have shown an increase of pathogenicity 
in strains treated with fluconazole (FLZ) in a model of 
systemic infection in rats (11). Other authors have shown 
an important FLZ effect on the capacity of adhesion and 
production of exoenzymes (12). One of the new bioma-
terials being used in Dentistry is chitosan (HMWC), a 
cationic polymer obtained from chitin (13). The effect 
on inhibition of C. albicans fungal adhesion to epithe-
lial cells and to hydroxyapatite pearls has been demon-
strated in vitro, as well as its use as a vehicle or adjuvant 
in antifungal action (3, 14-16). Seyfarth et al. showed an 
existing positive correlation between chitosan molecu-
lar weight and its effectiveness as an antifungal agent 
in an in vitro study (17). In this sense, the combination 
of treatments could reduce the employed dose, thus pre-
venting the development of antifungal resistance in the 
therapeutic treatment of this pathology. 
In this work, antifungal and post- antifungal effects of 
CLX, FLZ, HMWC and its combinations were assessed 
on some virulence factors of C. albicans after a short ex-
posure to these drugs in sub-inhibitory concentrations. 
Besides, the existing correlation between the mentioned 
factors was analyzed in the presence and in the absence 
of the antifungal agents under study. 
Materials and Methods 
Isolation and identification of 10 isolated wild C. albi-
cans strains
The strains were isolated from the saliva of 10 patients 
with oral candidiasis, having complete or partial den-
tures, who were assisted at Cathedra of Prosthodontics 
III, Faculty of Dentistry, National University of Cór-
doba, Argentina; a collection strain was isolated as well 
(C.albicans serotype A NCPF 3153 - CA 3153 - kindly 
provided by Dr. Jose Ponton, University of the Basque 
Country, Spain). The patients agreed to sing a consent 
form prior to their participation in the study. Patients who 
were under treatment with antifungal drugs, xerostomic 
drugs, or under a prolonged treatment with anti-inflam-
matory drugs 10 days prior to exam were excluded. The 
protocol was approved by the Ethics Committee, Polo 
Hospitalario, Córdoba, Argentina. Samples were har-
vested in Sabouraud glucose agar (SGA) with 1% chlo-
ramphenicol (Britania, Argentina); identification of C. 
albicans species was carried out through germinative 
tube development test, sugar assimilation and fermen-
tation (Candifast, International Microbe, France), and 
growth within a chromogenic medium (CHROMagar 
Candida, France) (18). The isolated yeasts were kept in 
sterile water at 4 ºC. 
Antifungal agents
Chlorhexidine solutions were used, 12.5-25-50 µg/ml 
chlorhexidine (CLX, Microsules Bernabó, Argentina), 
as well as 50-100-150 µg/ml fluconazole (FLZ, Pfizer, 
Argentina), 0.25 g% high-molecular-weight chitosan 
(HMWC 0,25% in acetic acid buffer pH 4, 90% dea-
cylated, 280 cps, PM 300 kDa, Unifarma Argentina) and 
their combinations (QAPM 0.25g% / CLX 50 µg/ml and 
QAPM 0.25 g% / FLZ 150 µg/ml) in phosphate saline 
buffer (PBS) pH 7.4. These concentrations, which are 
sub-inhibitory for yeasts, were previously determined 
in the isolated strains in our laboratory, and proved to 
coincide with the ones employed in our previous work 
and in other authors’ work (16,19,20). Minimum in-
hibitory concentration (MIC) was determined using the 
agar dilution method, which defines MIC as the lowest 
antifungal drug concentration where a considerable de-
crease in the colony size is observed compared to con-
trol growth. This method has shown a good correlation 
with the reference method (21). 
Yeast suspension preparation for the trials
Before the trials, isolated yeast strains were inoculated 
on SGA plates and incubated during 24 h at 37ºC. Sub-
sequently, suspensions were prepared in sterile PBS 
(absorbance: 1.500 at 520 nm). Then, 1 mL of suspen-
sion was added to 4 mL of PBS (control) or to 4 mL of 
PBS-antifungal agents in the aforementioned concen-
trations, resulting in a 1x106-1x107 cells/mL concentra-
tion. Tubes were incubated during 60 min at 37ºC with 
gentle agitation. Cells were washed twice with sterile 
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PBS (10 min at 3,000 rpm); later, they were resuspended 
in sterile PBS and adjusted to Abs520 nm = 0.800. After 
this, the viability was verified on SGA plates. Besides, 
viability of all strains was verified after treatment with 
acetic acid buffer pH 4; inhibition of growth was not 
observed. 
Determination of cell surface hydrophobicity (CSH)
Adhesion to hydrocarbons method was used to deter-
mine CSH. Yeast suspensions were mixed with chloro-
form (volume relationship 5:1); the mixture was agitated 
for 1 minute and put to rest during 10 min at 37ºC. CSH 
was defined as the difference between absorbances at 
520 nm of the aqueous phase before and after the con-
fronting C. albicans suspension and the organic phase, 
∆Abs (5). 
Germinative tube development (GT)
In order to induce GT development, 250 µl yeast sus-
pensions treated with antifungal drugs were mixed with 
1 mL of human serum, and incubated at 37ºC during 2.5 
hours. Once that time elapsed, 300 cells in continuous 
fields (X 400) in Neubauer chamber were counted and 
GT cells were expressed as a percentage (6). 
Determination of phospholipase activity (PL) 
PL activity of C. albicans strains was determined by 
a modified version of Vidotto s´ technique (6). A 0.075 
g% soy lecithin suspension (Herbaccion Isa, Argentina) 
with 0.056 g% CaCl2 and 5.84 g% NaCl was used in 
each plate of SGA. 10 µl of suspensions were inoculated 
in SGA supplemented with lecithin and incubated for 
72-96 hours at 37ºC. Each strain was tested in triplicate. 
The value of PL activity was determined as the quotient 
between the colony diameter plus halo and the colony 
diameter, Pz = (d col + d halo) / dcol (7). 
Determination of post antifungal effect (PAFE) 
In order to study the inhibitory effect on the recovery 
of fungal growth of the analyzed compounds, namely 
PAFE, 800 µL of C. albicans suspensions were incu-
bated with 1.2 mL of RPMI 1640 (American Biorgan-
ics, USA) during 24 h at 37ºC in a thermostatic bath 
with gentle agitation. Changes of absorbance at 520 nm 
were observed from the beginning of trial and after 24 
h (ΔAbs520nm). Thus, a greater value indicates a better 
recovery of the fungal growth and, therefore, a smaller 
PAFE (8). A period of 24 hours was selected as final 
time for absorbance record, after an experiment where 
the absorbance at 520 nm was recorded each hour, from 
time 0 to 32 h. 
All experiments were carried out in triplicate and data 
were statistically processed by ANOVA, Spearman’s 
correlation coefficient and Student’s t-test for independ-
ent samples (p<0.05). 
Results and Discussion
Germinative tube (GT) development 
In isolated C. albicans strains obtained from patients 
and treated with CLX, FLZ and HMWC, alone or com-
bined with the aforementioned compounds, a significant 
decrease of GT was observed (Fig. 1-a). The collection 
strain, CA 3153, showed significant decreases in GT 
after treatment with antifungal drugs and its combina-
tions, except for FLZ. The most significant decreases 
of GT were observed in the presence of CLX, which 
proved to be the most efficient antifungal agent regard-
ing proportional reductions of GT with concentrations 
(data not shown), in agreement with results observed  by 
Ellepola et al. (22). 
Cell surface hydrophobicity (CSH)
A significant CSH increase in isolated strains from pa-
tients was observed (Fig. 1-b) and also in CA 3153 af-
ter treatment with HMWC, HMWC/CLX and HMWC/
FLZ. No significant differences were observed after 
treating strains only with CLX or FLZ. These results 
do not agree with those observed by Anil et al. (20) 
and ours on previous works (3), although employing 
the same concentrations (50 µg/ml). This could be ex-
plained by the differences in the experimental condi-
tions, since in the present study yeast suspensions are 
within a solution in contact with antifungics in short 
times, which implies contact on cell surface and would 
represent a similar situation as the one occurring during 
the use of oral rinses. Goldberg et al. (23) found results 
similar to ours in the presence of HMWC, assigning the 
CSH increase to the polycationic character of chitosan, 
and this would cause a decrease of superficial negative 
charge of yeasts and the subsequent increase of cellu-
lar hydrophobicity (17,23). Lack of effect on CSH when 
strains were treated with antifungics in the absence of 
HMWC indicates that the polycationic polymer would 
be responsible for the observed effect, without syner-
gism when combined with CLX and FLZ.
Determination of post antifungal effect (PAFE) 
Isolated strains from patients and CA 3153 showed a sig-
nificant decrease in the growth recovery when they were 
treated with CLX (Figure 1-c). FLZ produced a significant 
decrease of CA 3153 growth recovery. In the presence 
of HMWC, alone or combined with FLZ, an increasing 
tendency in the growth recovery was observed. These re-
sults show that the significant decrease observed in the 
presence of CLX or FLZ is counteracted in the presence 
of HMWC, the effect of which prevails when antifungal 
drugs are combined with it. Previous results have shown 
the antifungal effect of dissolved chitosan within the sol-
id medium of yeast growth (3); nevertheless, the experi-
mental conditions of this work have been different, as it 
has been discussed in a previous section; this is likely to 
be this way due to the short period contact, similarly to 
what happens in the case of an oral rinse.
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Determination of phospholipase activity (PL) 
All isolated C. albicans strains obtained from patients 
and CA 3153 exhibited PL activity. When they were 
treated with the analyzed antifungal agents, CA 3153 
showed a significant decrease of PL activity in the pres-
ence of CLX, which proved directly proportional to con-
centrations, in accordance with Kadir et al’s findings 
(7). In isolated strains from patients no differences were 
observed in PL activity with the different treatments 
(Fig. 1-d). This difference in the behavior between iso-
lated strains from patients and CA 3153 may arise from 
the fact that these, due to their wild condition, could 
be adapted more easily through other mechanisms to 
overcome environmental difficulties or host immunity 
mechanisms, resulting in more resistant strains when 
treated with antifungal drugs. 
Correlation among the analyzed virulence factors 
A strong positive correlation among the analyzed viru-
lence factors was observed in isolated untreated strains 
(r2> 0.73 and p < 0.03). These results corroborate the 
cooperative effect of these factors, which is a breeding 
ground for the development of yeast virulence and, in 
turn, the illness, in accordance with Vidotto et al. (6). 
Other authors (24) have shown the coordinated action 
of virulence factors, such as the contribution to fungal 
nutrition and the micro-environmental modification 
produced by fatty acid liberation from fungal lipase ac-
tivity. Such liberation benefits exoenzymes proteinases 
activity, producing a pH decrease to values between 5.5 
and 2.8. Additionally, fatty acid liberation improves C. 
albicans adhesion to host surfaces. Besides, Masuoka 
et al. correlated the composition of C. albicans cell wall 
(long of chain of the acid-labile portion) with change in 
the fungal hydrophobicity (25). 
When treating yeasts with the analyzed antifungics, 
CLX produced positive correlations among all the fac-
tors (p < 0.002); and FLZ produced the same effect on 
GT, PAFE and PL activity (p < 0.02). HMWC produced 
strong positive correlations (p < 0.02), except between 
PAFE and PL activity. When combining HMWC with 
CLX, a strong positive correlation was observed be-
tween the factors (r2 > 0.7 - p <0.002), except for GT and 
PAFE, while HMWC combined with FLZ did not pro-
duce significant associations. The combined use of anti-
fungal drugs has been evaluated by many authors. Senel 
et al. (in vitro studies) (26) and Giunchedi et al. (in vivo 
studies) (27) obtained good results, showing that chi-
tosan produced an adjuvant effect on liberation and ef-
fectiveness of drugs to which the former was associated 
in those studies. In accordance with our results, Ellepo-
la et al. showed a strong correlation between virulence 
factors after treating C. albicans strains with CLX (22). 
Nevertheless, CLX is not habitually used by clinicians 
in our country for oral candidiasis treatment, consid-
ering its effects on the sense of taste and the staining 
of oral tissues and acrylic dentures (28). In this work, 
after combining HMWC with FLZ, a drastic effect on 
the capacity for GT development was observed. Con-
sidering the fact that GT development implies not only 
morphological changes but also a greater capacity for 
infection and penetration of oral soft tissues, this work 
contributes evidences to the results obtained by other 
authors in this area. 
The use of virulence factors as gravity predictors of fun-
gal infections or as in vitro models for studying C. albi-
cans behavior should be carefully analyzed. Though our 
results show that GT development is very sensitive to 
the antifungal treatment, it should not be considered as 
an only parameter or predictor of fungal virulence. The 
strong correlation observed in the fungus virulence factors 
involved in infections shows that an individual evaluation 
of them would be a simplification of the analysis, consider-
ing that not all the factors are expressed in infections or 
necessarily in a particular stage of infection (29). 
Ellepola et al. have shown that a combined treatment 
with antifungics would act as adjuvants in denture-
related oral candidiasis and would allow diminishing 
Fig. 1. Effect of chlorhexidine (CLX), fluconazole (FLZ), high mo-
lecular weight chitosan (HMWC) and its combinations on virulence 
factors of C. albicans isolated from patients. a) germinative tube 
development percentage, GT b) cell surface hydrophobicity, CSH, 
as ΔAbs520 nm c) post-antifungal effect, PAFE, as ΔAbs520nm d) 
phospholipase activity, Pz.
* indicates significant differences respect to control; p <0.05. 
          CONTROL  CLX      FLZ  HMWC  HMWC+CLX  HMWC+FLZ 
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medicine doses, thus preventing the development of 
antifungal resistance (22). These authors conclude that 
clinical manifestations in oral candidiasis and recent 
advances in antifungal generation give a new clinical 
meaning to the post-antifungal effect concept, consider-
ing it as an in vitro model for evaluation of therapeutic 
treatment in the future. 
Although intra-oral concentrations of antifungals can 
fluctuate considerably in oral cavity, our results indicate 
that sub-inhibitory concentrations of antifungics used 
diminish the infection capacity of C. albicans, repre-
sented by virulence factors, in accordance with other 
authors (7). In clinical terms, our results would indicate 
that short exposures to sub-inhibitory concentrations 
with the analyzed drugs would be able to modulate the 
expression of the virulence factors studied and therefore, 
to facilitate the elimination of oral cavity microorgan-
isms, and to decrease Candida’s patogenicity, in spite of 
the brief exposure period in the oral environment. 
Conclusions 
The present work was based on the effect that short ex-
posures of antifungals to sub-inhibitory concentrations 
has on virulence factors of C. albicans, the most im-
portant etiologic agent of oral candidiasis. Our results 
suggest that adhesion, represented by the evaluation of 
CSH, exoenzymes production, dimorphism and growth 
recovery after treatment with antifungals in short peri-
ods, can be factors that add to the predisposing condi-
tions of host and, in turn, determine the development of 
candidiasis or the status of patients as healthy carriers. 
On the other hand, this study confirms that antifung-
ics used would be able to modulate the development of 
candidiasis. 
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